|
|
|
|
|
1. |
Blitzer PH. Epidemiology of head and neck cancer. Semin Oncol 1988; 15:2-9. |
2. |
Parker SL, Tong T, Bolden S, et al. Cancer Statistics 1996. CA Cancer J Clin 1996; 46:5-27. |
3. |
Myers EM. Head and neck oncology. Diagnosis, treatment and rehabilitation. Boston: Little, Brown and Co.; 1991. |
4. |
Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 1990; 61:779-87. |
5. |
Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer, larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53:5113-20. |
6. |
Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancer. Br Med Bull 1991; 47:87-98. |
7. |
Shin DM, Ro JY, Hong WK et al. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:3153-9. |
8. |
Fernández A, Pérez R, Macías A, et al. Generation and primary characterization of monoclonal antibodies against epidermal growth factor receptor. Interferon Biotechnol 1989; 6:289-298. |
9. |
Fernández A, Spitzer E, Pérez R, et al. A new monoclonal antibody for detection of R-EGF-receptors in Western Blots and paraffin-embedded tissue sections. J Cell Biochem 1992; 49:157-165. |
10. |
Ramos-Suzarte M, Rodríguez N, Oliva JP, et al. 99mTc-Labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 1999; 40:768-775. |
11. |
Hiratsuka H, Miyakawa A, Nakamori K, et al. Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer 1997; 80:351-6. |
12. |
Liu M, Weynard B, Delos M, et al. Prognostic factors in squamous cell carcinomas of the head and neck. Acta Otorhinolaryngol Belg 1999; 53:155-60. |
13. |
Furukawa M, Kanelo M, Mochimatsu I, et al. Comparative studies of diagnosis with US or CT of the cervical lymph node metastases in head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho 1991; 94:577-86. |
14. |
Feinmesser R, Freeman JL, Noyek AM, et al. MRI and neck metastases: a clinical, radiological, pathological correlative study. J Otolaryngol 1990; 19:136-40. |
15. |
Wilson GR, McLean NR, Chippindale A, et al. The role of MRI scanning in the diagnosis of cervical lymphadenopathy. Br J Plast Surg 1994; 47:175-9. |
16. |
Gong QY, Zheng GL, Zhu HY. MRI differentiation of recurrent nasopharyngeal carcinoma from postradiation fibrosis. Comput Med Imaging Graph 1991; 15:423-9. |
17. |
Fujii M, Kanzaki J. The role of MRI for the diagnosis of recurrence of nasopharyngeal cancer. Auris Nasus Larynx 1994; 21:32-7. |
18. |
Maurizi M, Scambia G, Benedetti P, et al. EGF-R expression in primary laryngeal cancer: correlation with clinic-pathological features and prognostic significance. Int J Cancer 1992; 52:862-66. |
19. |
Iznaga-Escobar N, Torres LA, Morales A, et al. Technetium-99m-labeled anti-EGF-Receptor antibody in patients with tumor of epithelial origin: I Biodistribution and Dosimetry for radioimmunotherapy. J Nucl Med 1998; 39:15-23. |
20. |
Soo KC, Ward M, Roberts KR, et al. Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head Neck Surg 1987; 9:349-52. |
21. |
Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73:228-35. |
22. |
Heissler E, Grunert B, Barzen G, et al. Radioimmunoscintigraphy of squamous cell carcinoma in the head and neck region. Int J Oral Maxillofac Surg 1994; 23:149-52. |
23. |
Van Dongen GA, Leverstein H, Roos JC, et al. Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab´)2. Cancer Res 1992; 52:2569-74. |
24. |
Adamietz IA, Baum RP, Schemman F, et al. Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT. J Nucl Med 1996; 37:1942-1946. |
25. |
Kostakoglu L, Uysal U, Ozyar E, et al. A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24:621-8. |
26. |
Kostakoglu L, Uysal U, Ozyar E, et al. Pre- and post-therapy thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med 1996; 37:1956-62. |
27 |
Leitha T, Glaser C, Pruckmayer M, et al. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion. J Nucl Med 1998; 39:1166-71. |
28. |
Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38:312-8. |
29. |
Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255-60. |
30. |
Stokkel MP, Bongers V, Hordijk GJ, et al. FDG Positron emission tomography in head and neck cancer. Pitfall or Pathology?. Clin Nucl Med 1999: 24:950-54. |
31. |
Morales-Morales A, Duconge J, Caballero-Torres I, et al. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol 1999; 26:275-9. |
El presente trabajo fue financiado por la Comisión Honoraria de Lucha Contra el Cáncer, Montevideo, Uruguay. |
|
|
|